Healxan, the Cambridge-based AI-enabled, clinical-stage biotech company dedicated to rare diseases, has appointed Dr ...

UK artificial intelligence specialist Healx has begun a partnership with two medical charities that aims to uncover new therapies for the neurodegenerative disease Friedreich's ataxia (FA).

Healx, a leading AI-driven drug discovery company focused on rare diseases, announces Christopher Moertel, M.D., as Global Head of Clinical Development We are thrilled to welcome Dr. Moertel to Healx.

Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 ...

SMi Reports: AI HealthTech Company Healx, who raised $10m to advance drug discovery and treatments for rare diseases, are set to speak at the 8 th Annual Orphan Drugs and Rare Diseases Conference ...

With its Healnet platform, Healx pairs cutting-edge AI with industry-leading drug discovery and rare disease expertise to identify new uses for known compounds. The company now has over 20 ...

In an industry often driven by the relentless race to innovate, Healx is setting a new standard – one where technology meets care, and innovation has a direct line to patients. By harnessing the power ...

Healx, a leading AI-driven drug discovery company focused on rare diseases, announces Christopher Moertel, M.D., as Global ...